PMID- 38526917
OWN - NLM
STAT- MEDLINE
DCOM- 20240429
LR  - 20240429
IS  - 1473-5687 (Electronic)
IS  - 0954-691X (Linking)
VI  - 36
IP  - 6
DP  - 2024 Jun 1
TI  - Vonoprazan-amoxicillin dual therapy with different amoxicillin dosages for 
      treatment-naive patients of Helicobacter pylori infection in China: a 
      prospective, randomized controlled study.
PG  - 712-719
LID - 10.1097/MEG.0000000000002760 [doi]
AB  - BACKGROUND: The vonoprazan (VPZ)-amoxicillin (AMO) dual therapy (VA) demonstrates 
      a satisfactory eradication rate for Helicobacter pylori (H. pylori ). However, 
      the optimal dosage of AMO in this regimen remains uncertain. The objective of 
      this study is to investigate the efficacy of different doses of AMO in the VA 
      regimen for first-line treatment of H. pylori infection. METHODS: A total of 192 
      treatment-naive H. pylori -infected patients were randomly assigned to one of 
      three groups: low-dose VA (LD-VA: VPZ 20 mg b.i.d + AMO 750 mg t.i.d), 
      moderate-dose VA (MD-VA:VPZ 20 mg b.i.d + AMO 1000 mg t.i.d), and high-dose VA 
      (HD-VA: VPZ 20 mg b.i.d + AMO 1250 mg t.i.d). All groups received 14 days of 
      treatment. The study evaluated and compared the eradication rates, adverse events 
      (AEs), and patient compliance among the three groups. RESULTS: Eradication rates 
      for LD-VA, MD-VA, and HD-VA were 76.6% (49/64), 79.7% (51/64), and 84.4% (54/64), 
      respectively, as determined by intention-to-treat analysis; 90.6% (48/53), 94.3% 
      (50/53), and 98.1% (53/54) according to per-protocol analysis; 89.1% (49/55), 
      94.4% (51/54), and 96.4% (54/56) with modified intention-to-treat analysis (all P 
       > 0.05). Although not statistically significant, numerically higher eradication 
      rates were observed with the higher dose AMO VA regimen. There were no 
      statistically significant differences in the incidence of AEs and compliance 
      among the three VA regimens. CONCLUSION: Fourteen-day VA regimens with AMO doses 
      exceeding 2 g/day demonstrated satisfactory eradication rates. HD-VA therapy is 
      potentially the most effective regimen. Large-sample clinical trials are required 
      to further validate these findings.
CI  - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Liu, Zhu
AU  - Liu Z
AD  - Department of Gastroenterology and Hepatology, Tianjin Medical University General 
      Hospital, Tianjin Institute of Digestive Disease, Tianjin Key Laboratory of 
      Digestive Diseases, Tianjin.
AD  - Department of Gastroenterology, Shandong Provincial Maternal and Child Health 
      Care Hospital Affiliated to Qingdao University, Jinan.
FAU - Sun, Dongjie
AU  - Sun D
AD  - Department of Digestive Diseases, The Fuzong Clinical Medical College, Fujian 
      Medical University, Fuzhou, China.
FAU - Kou, Luan
AU  - Kou L
AD  - Department of Gastroenterology, Shandong Provincial Maternal and Child Health 
      Care Hospital Affiliated to Qingdao University, Jinan.
FAU - Jia, Li
AU  - Jia L
AD  - Department of Gastroenterology, Shandong Provincial Maternal and Child Health 
      Care Hospital Affiliated to Qingdao University, Jinan.
FAU - Hao, Jiaorong
AU  - Hao J
AD  - Department of Gastroenterology, Shandong Provincial Maternal and Child Health 
      Care Hospital Affiliated to Qingdao University, Jinan.
FAU - Zhou, Jihai
AU  - Zhou J
AD  - Department of Gastroenterology, Shandong Provincial Maternal and Child Health 
      Care Hospital Affiliated to Qingdao University, Jinan.
FAU - Zheng, Wenwen
AU  - Zheng W
AD  - Department of Gastroenterology, Shandong Provincial Maternal and Child Health 
      Care Hospital Affiliated to Qingdao University, Jinan.
FAU - Gao, Fengyu
AU  - Gao F
AD  - Department of Gastroenterology, Shandong Provincial Maternal and Child Health 
      Care Hospital Affiliated to Qingdao University, Jinan.
FAU - Chen, Xin
AU  - Chen X
AD  - Department of Gastroenterology and Hepatology, Tianjin Medical University General 
      Hospital, Tianjin Institute of Digestive Disease, Tianjin Key Laboratory of 
      Digestive Diseases, Tianjin.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20240319
PL  - England
TA  - Eur J Gastroenterol Hepatol
JT  - European journal of gastroenterology & hepatology
JID - 9000874
RN  - 0 (Sulfonamides)
RN  - 0 
      (1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine)
RN  - 804826J2HU (Amoxicillin)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Pyrroles)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Humans
MH  - *Helicobacter Infections/drug therapy
MH  - *Sulfonamides/administration & dosage
MH  - *Amoxicillin/administration & dosage
MH  - Male
MH  - Female
MH  - Middle Aged
MH  - *Helicobacter pylori/drug effects
MH  - *Drug Therapy, Combination
MH  - *Anti-Bacterial Agents/administration & dosage/adverse effects
MH  - Prospective Studies
MH  - *Pyrroles/administration & dosage/adverse effects
MH  - Adult
MH  - China
MH  - Treatment Outcome
MH  - *Proton Pump Inhibitors/administration & dosage/adverse effects
MH  - Aged
EDAT- 2024/03/25 18:42
MHDA- 2024/04/29 13:58
CRDT- 2024/03/25 12:53
PHST- 2024/03/25 18:42 [pubmed]
PHST- 2024/04/29 13:58 [medline]
PHST- 2024/03/25 12:53 [entrez]
AID - 00042737-990000000-00330 [pii]
AID - 10.1097/MEG.0000000000002760 [doi]
PST - ppublish
SO  - Eur J Gastroenterol Hepatol. 2024 Jun 1;36(6):712-719. doi: 
      10.1097/MEG.0000000000002760. Epub 2024 Mar 19.